Genprex, Inc. (NASDAQ:GNPX) Short Interest Down 37.6% in December

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 396,100 shares, a decrease of 37.6% from the December 15th total of 634,600 shares. Based on an average daily trading volume, of 9,330,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 4.8% of the company’s stock are sold short.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC grew its position in Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent filing with the SEC. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Stock Performance

Shares of NASDAQ GNPX remained flat at $0.70 during trading hours on Thursday. 169,713 shares of the company traded hands, compared to its average volume of 449,371. The business’s 50 day moving average is $1.05 and its 200 day moving average is $1.13. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $13.00.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.